Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

Johnson and Johnson
Teva
Healthtrust
Julphar
US Army
Cipla
Deloitte
Argus Health
Express Scripts
Dow

Generated: August 21, 2017

DrugPatentWatch Database Preview

Details for New Drug Application (NDA): 021443

« Back to Dashboard
NDA 021443 describes ENJUVIA, which is a drug marketed by Teva Branded Pharm and is included in one NDA. It is available from one supplier. There are two patents protecting this drug. Additional details are available on the ENJUVIA profile page.

The generic ingredient in ENJUVIA is estrogens, conjugated synthetic b. There are three drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the estrogens, conjugated synthetic b profile page.

Summary for NDA: 021443

Tradename:
1
Applicant:
1
Ingredient:
1
Patents:2
Formulation / Manufacturing:see details

Suppliers and Packaging for NDA: 021443

Tradename Generic Name Dosage NDA Application Type Supplier National Drug Code Package Code Package
ENJUVIA
estrogens, conjugated synthetic b
TABLET;ORAL 021443 NDA Physicians Total Care, Inc. 54868-6163 54868-6163-0 10 TABLET in 1 BOTTLE (54868-6163-0)
ENJUVIA
estrogens, conjugated synthetic b
TABLET;ORAL 021443 NDA Physicians Total Care, Inc. 54868-6163 54868-6163-1 30 TABLET in 1 BOTTLE (54868-6163-1)

Summary for product number 001

Active Rx/OTC/Discontinued:RXDosage:TABLET;ORALStrength0.3MG
Approval Date:Dec 20, 2004TE:RLD:No
Patent:► SubscribePatent Expiration:Mar 8, 2021Product Flag?YSubstance Flag?YDelist Request?
Patented Use:TREATMENT OF MODERATE TO SEVERE VAGINAL DRYNESS AND PAIN WITH INTERCOURSE, SYMPTOMS OF VULVAR AND VAGINAL ATROPHY, ASSOCIATED WITH MENOPAUSE
Patent:► SubscribePatent Expiration:Feb 12, 2021Product Flag?YSubstance Flag?YDelist Request?
Patented Use:TREATMENT OF MODERATE TO SEVERE VAGINAL DRYNESS AND PAIN WITH INTERCOURSE, SYMPTOMS OF VULVAR AND VAGINAL ATROPHY, ASSOCIATED WITH MENOPAUSE
Patent:► SubscribePatent Expiration:Mar 8, 2021Product Flag?YSubstance Flag?YDelist Request?
Patented Use:TREATMENT OF MODERATE TO SEVERE VASOMOTOR SYMPTOMS ASSOCIATED WITH MENOPAUSE


Complete Access Available with Subscription
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

Boehringer Ingelheim
US Department of Justice
Medtronic
Fish and Richardson
Express Scripts
Farmers Insurance
Deloitte
Harvard Business School
US Army
Moodys

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted Heap | Mobile and Web Analytics
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot